1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | CORL105; COR-L 105 |
| Species | Human |
| Cat.No | ABC-TC0178 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
COR-L105 is a human non-small cell lung cancer (NSCLC) cell line established from the pleural effusion of a Caucasian male patient with lung adenocarcinoma. The cells exhibit an epithelial-like morphology and grow partially attached and in suspension without forming a confluent monolayer. Functionally, COR-L105 cells may be involved in tumor microenvironment regulation and amino acid metabolic reprogramming due to high expression of genes such as PPBP and SLC6A14. Its complex karyotype (containing at least 15 chromosomal translocations) reflects the genomic instability of NSCLC. Although the in vivo tumorigenicity has not been fully clarified, this cell line has been widely used in the study of the mechanism of lung adenocarcinoma, including: the molecular pathway of apoptosis induced by histone deacetylase inhibitors (HDACi) and the adhesion mechanism of tumor cells to brain endothelial cells, providing an in vitro model for the study of NSCLC brain metastasis.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
COR-L105 can be used to study the mechanism of action of histone deacetylation in the progression of NSCLC. These cells can also be used to evaluate the pro-apoptotic effects of histone deacetylase inhibitors (HDACi) and explore the regulatory network of CIP/KIP family proteins. COR-L105 can also be applied to screen potential drug targets that inhibit blood-brain barrier penetration and provide an experimental model for anti-metastatic therapy.
